UNITE	D STAT	ES S	_		-		NGE C	OMMI	SSION			/AL		
Section 16. Form 4 or Form 5 obligations may continue. See					a) of the Secu	OMB Number:         3235-0287           Estimated average burden            hours per response:         0.5								
1. Name and Address of Reporting Person <sup>*</sup> <u>Ticho Barry</u>			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Stoke Therapeutics, Inc.</u> [STOK ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				
(Middle) S, INC.		03/27/	2024						below)	EF MEDICA	below) AL OFFICEF			
		4. If Am	endment, I	Date o	of Original Fil	ed (Month/Da	ay/Year)	Line	)	•	0.			
01730											han One Repor	ting		
(Zip)		Rule 10b5-1(c) Transaction Indication												
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
Date			2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed		ties Acquired (A) or d Of (D) (Instr. 3, 4 and		Securitie Beneficia Owned F	s Fo ally (D ollowing (D	orm: Direct D) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code V	Amount	(A) or (D)	Price	Transact	ion(s)		iiisti. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)														
Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		ransaction code (Instr. ) Securities Acquired (A) or Disposed		ive ies ed ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Co	de V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
24	A		60,000		(1)	03/26/2034	Common Stock	60,000	\$ <b>0</b>	60,000	D			
24	А		40,000		(3)	03/15/2028	Common Stock	40,000	\$0	40,000	D			
	s STA erson <sup>•</sup> (Middle) S, INC. 01730 (Zip) Table I - No Table II - on Year) 3A. Deeme Execution if any (Month/Da	statemen (Middle) (Middle) (Middle) (Alternation of the second of th	STATEMENT OF Filed pursuan or Sec erson*  (Middle)  (Middle)  (Include)  (Zip)  Table I - Non-Derivative Sec (Month/Day/Year)  Table II - Derivative Sec (Month/Day/Year)  (Month/Day/Year)  Code (Instr. a)  Code (Instr. b)  Code (V  Code V  Code V	STATEMENT OF CHAN Filed pursuant to Section or Section 30(h) d arson* (Middle) S, INC. (Middle) S, INC. (Zip) 2. Issuer Name ar Stoke Theray 3. Date of Earliest 03/27/2024 4. If Amendment, 4. If Amendment, Check this box satisfy the affin Check this box Scutter A a affin Check this box Scutter Check thi	STATEMENT OF CHANGE         Filed pursuant to Section 30(h) of the         erson*       2. Issuer Name and Tic         (Middle)       3. Date of Earliest Trans 03/27/2024         (Middle)       3. Date of Earliest Trans 03/27/2024         (Middle)       4. If Amendment, Date         01730       Rule 10b5-1(c)         (Zip)       Check this box to ind satisfy the affirmative         Table 1 - Non-Derivative Securities Acc (Month/Day/Year)       2A. Deemed Fany (Month/Day/Year)         3A. Deemed Execution Date, if any (Month/Day/Year)       5. Number of Derivative Scurities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)         24       A       60,000	Washington, D.C. 24         STATEMENT OF CHANGES IN BE         Filed pursuant to Section 16(a) of the Secur or Section 30(h) of the Investment Core or Section 30(h) of the Investment Core Stoke Therapeutics, Inc.         arson*       2. Issuer Name and Ticker or Trading Stoke Therapeutics, Inc.         (Middle)       3. Date of Earliest Transaction (Mont 03/27/2024         01730       4. If Amendment, Date of Original File         01730       Check this box to indicate that a transatify the affirmative defense condition         Table 1 - Non-Derivative Securities Acquired, Dist (Month/Day/Year)         2. Transaction Date (Month/Day/Year)       2. Deemed Execution Date, if any (Month/Day/Year)       3. Transacti Code (nstr. 3. A. Deemed Execution Date, if any (Month/Day/Year)       3. Date Securities Acquired, Dist (Code (nstr. 3. 4 and 5)         34. Deemed Execution Date, if any (Month/Day/Year)       4. Code (nstr. 3. 4 and 5)       5. Number of Code (nstr. 3. 4 and 5)       6. Date Exercisable         24       A       60,000       (1)	STATEMENT OF CHANGES IN BENEFICI         Filed pursuant to Section 16(a) of the Securities Exchar or Section 30(h) of the Investment Company Act         arson       2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK]         (Middle)       3. Date of Earliest Transaction (Month/Day/Year) 03/27/2024         (Middle)       3. Date of Earliest Transaction (Month/Day/Year)         01730       A. If Amendment, Date of Original Filed (Month/Day/Year)         (Zip)       Check this box to indicate that a transaction was n satisfy the affirmative defense conditions of Rule 1         Table 1 - Non-Derivative Securities Acquired, Disposed of (Month/Day/Year)       3. Transaction (Date (Month/Day/Year)       3. Transaction to be code (Instr. 8)       4. Securities (Month/Day/Year)         Masser       1. Transaction (e.g., puts, calls, warrants, options, convertive (e.g., puts, calls, warrants, options, convertive (A(A) or Disposed of (D) (Instr. 3, 4 and 5)       6. Date Exercisable and Expiration Date (Month/Day/Year)         Masser       4. and 60,000       (1)       03/26/2034	Washington, D.C. 20549         STATEMENT OF CHANGES IN BENEFICIAL OW         Filed pursuant to Section 16(a) of the Investment Company Act of 1940         arson"         2. Issuer Name and Ticker or Trading Symbol         Stoke Therapeutics, Inc. [STOK]         3. Date of Earliest Transaction (Month/Day/Year)         03/27/2024         4. If Amendment, Date of Original Filed (Month/Day/Year)         01730         (Zip)         Check this box to indicate that a transaction Indication         Date       Check this box to indicate that a transaction was made pursual satisfy the affirmative defense conditions of Rule 10b5-1(c). Set         Table 1 - Non-Derivative Securities Acquired, Disposed of (D) (Instr. Bay         Month/Day/Year)       A. Deemed Execution Date, If any (Month/Day/Year)       3. Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible securities acquired, Disposed of (D) (Instr. Bay (Month/Day/Year)       1. Transaction Date, If any (Month/Day/Year)       1. Transaction of a securities acquired (A) or Date, If any (Month/Day/Year)       1. The and the privative Securities Acquired (A) or Date, If any (Month/Day/Year)       1. The and the privative Securities Acquired (A) or Date, If any (Month/Day/Year)       1. The and the privative Securities Acquired (A) or Date, If any (Month/Day/Year)       1. The and the privative Securities Acquired (A) or Date, If any (Month/Day/Year)       1. The and the privative Securi	Washington, D.C. 20549         STATEMENT OF CHANGES IN BENEFICIAL OWNERS         Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940         arson*       Clisuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK]         (Middle)       3. Date of Earliest Transaction (Month/Day/Year)       6. In Line         01730       3. Date of Earliest Transaction Indicate Interpretion States (Month/Day/Year)       6. In Line         01730       Cipp       Check this box to indicate that a transaction vase made pursuant to a control satisfy the affirmative defense conditions of Rule 1005-1(c). See Instruction         Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Month/Day/Year)         2A. Deemed (Month/Day/Year)       3. Transaction (Fary Month/Day/Year)       3. Transaction (Socie (Instr. 9)       4. Securities Acquired (A) or Securities Acquired, Disposed of, or Beneficially Code (Instr. 9)         State I - Derivative Securities Acquired, Disposed of, or Beneficially (e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year)       5. Number Securities Acquired (A) or Disposed of (I) (Instr. 3: A and 9)       7. Title and Amount Number of (I) (Instr. 3: A d and 9)         A do 0000	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP         Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(f) of the Investment Company Act of 1940         strson*       2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK]       5. Relationship of Check all applied Direct Oliver of Stoke Therapeutics, Inc. [STOK]         (Middle)       3. Date of Earliest Transaction (Month/Day/Year)       6. Individual or Line)         (Middle)       3. Date of Earliest Transaction (Month/Day/Year)       6. Individual or Line)         (Zip)       Rule 10b5-1(c) Transaction Indication         (Zip)       Check this box to indicate that a transaction was made pursuant to a contract, instruction satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.         Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year)       3. Transaction Execution Date, from y Month/Day/Year)       3. Transaction Code (Instr. 9)       3. Securities Acquired (A) or Securities Code (Instr. 9)       5. Aurous Securities Code (Instr. 9)         n       A. Deerivative Securities Acquired, Disposed of, or Beneficially Owned (Bonth/Day/Year)       5. Number Code (Instr. 9)       7. Transaction Code (Instr. 9)       7. Transaction Code (Instr. 9)       7. Transaction Code (Instr. 9)       8. Price of Code (Instr. 9)         n       A. Deerivative Securities Acquired, Disposed of, or Beneficially Owned Code (Instr. 9)       7. Securities Code Code (Instr. 9)       7. Transaction Code (Instr. 9	Washington, D.C. 20549           STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP           Filed pursuant to Section 18(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940           State Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [ STOK ]           (Middle)         3. Date of Earliest Transaction (Month/Day/Year)         5. Relationship of Reporting 10 (Check all applicable)           01730         3. Date of Earliest Transaction (Month/Day/Year)         6. Individual or Joint/Group F (Port filed by More I Person           01730         Rule 10b5-1(c) Transaction Indication         6. Individual or Joint/Group F (Port filed by More I Person           01730         Cip)         Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plate Satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.           Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities and ship (Month/Day/Year)           a.         Transaction (a.g., quts, calls, warrants, options, convertible securities)         5. Securities Securities (Instr. 5)         6. Securities Securities (Instr. 6)           odd         A         60,000         (I)         03/26/2034         Common (Instr. 6)         9. Number Securities         9. Number Securities         9. Number Securities         9. Number Securities	Number         Control         Control <thcontrol< th=""> <thcontrol< th=""> <thc< td=""></thc<></thcontrol<></thcontrol<>		

xplanation of Responses:

1. The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

3. The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date.

/s/ Jonathan Allan, Attorney-in-06/07/2024 Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.